EUVIMEDEUVIMED entdecken
Open Access

Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study

Faranak Ebrahimian Sadabad iD, Tommaso Volpi iD, Praveen Honhar iD, Sule Tinaz iD, Mark Dias, Takuya Toyonaga, Mika Naganawa, Jean-Dominique Gallezot, Yanghong Yang, Waleed Ibrahim, Brian Pittman, Salih Cayir iD und 7 weitere

Movement Disorders · 2025-12 · 40 (12) · 2678-2687

DOI: 10.1002/mds.70041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 03.10.2025. Verfasst von Faranak Ebrahimian Sadabad und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Synapses. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIDA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

18 F‐FE‐PE2I is a highly selective dopamine transporter (DAT) positron emission tomography (PET) radioligand, whereas 11 C‐UCB‐J targets synaptic vesicle glycoprotein 2A (SV2A), enabling the assessment of synaptic density. Both tracers show significant alterations in Parkinson's disease (PD) in nigrostriatal regions. However, the extent of overlap between overall synaptic loss and dopaminergic denervation across different disease stages remains unclear.

Objective

To evaluate similarities and differences between patterns of DAT and SV2A binding in healthy controls (HC) and PD patients at different disease stages.

Methods

Thirty patients with PD (12 women, age: 65.8 ± 7.1 years) and thirteen HCs (7 women, age: 57.8 ± 5.4 years) underwent PET imaging with 18 F‐FE‐PE2I and 11 C‐UCB‐J on separate days. Patients with PD were also stratified by disease duration into two subgroups (6 years, n = 11). Binding potentials ( BP ND ) were quantified in four regions of interest (ROIs): caudate, putamen, ventral striatum (VS), and substantia nigra (SN). Between‐group differences in BP ND were evaluated against HCs for each tracer, and correlations between 18 F‐FE‐PE2I and 11 C‐UCB‐J BP ND were evaluated.

Results

In HCs, significant correlations were observed between caudate 18 F‐FE‐PE2I and striatal 11 C‐UCB‐J BP ND (caudate, putamen, VS). In PD (full cohort and longer‐duration subgroup), significant correlations emerged between SN 11 C‐UCB‐J and striatal 18 F‐FE‐PE2I. Percent differences between patients with PD and HCs with 18 F‐FE‐PE2I and 11 C‐UCB‐J were similar only in the SN.

Conclusions

This study examined the relationship between DAT and overall synaptic density in nigrostriatal ROIs in PD using dual‐tracer PET imaging, and there were distinct patterns that vary across disease stages. Understanding the interplay between dopaminergic and presynaptic degeneration in PD could enhance our knowledge of its pathophysiology and contribute to improve diagnosis. © 2025 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePositron-Emission TomographyDopamine Plasma Membrane Transport ProteinsSynapsesHumansFemaleMiddle AgedMaleAgedNerve Tissue ProteinsMembrane GlycoproteinsSubstantia Nigra

Stichwörter der Autor:innen

PDPETSV2Adopamine

Substanzen

Dopamine Plasma Membrane Transport ProteinsSV2A protein, humanNerve Tissue ProteinsMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
  • Department of Neurology, Yale University, New Haven, CT, USA.
  • Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  • AbbVie, North Chicago, IL, USA.

ORCID-Profile: Faranak Ebrahimian Sadabad, Tommaso Volpi, Praveen Honhar, Sule Tinaz, Salih Cayir

Förderung

  • NIH HHS
  • NIDA NIH HHS
  • NINDS NIH HHS
  • NIMH NIH HHS
  • National Institutes of Health

Zitieren

APA

Sadabad, F. E., Volpi, T., Honhar, P., Tinaz, S., Dias, M., Toyonaga, T., Naganawa, M., Gallezot, J. D., Yang, Y., Ibrahim, W., Pittman, B., Cayir, S., Radhakrishnan, R., Angarita, G. A., Holmes, S. E., Comley, R., Carson, R. E., Finnema, S. J., & Matuskey, D. (2025). Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders, 40(12), 2678-2687. https://doi.org/10.1002/mds.70041

Vancouver

Sadabad FE, Volpi T, Honhar P, Tinaz S, Dias M, Toyonaga T, et al. Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study. Movement Disorders. 2025;40(12):2678-2687. doi:10.1002/mds.70041

BibTeX
@article{Sadabad2025,
  author = {Sadabad, Faranak Ebrahimian and Volpi, Tommaso and Honhar, Praveen and Tinaz, Sule and Dias, Mark and Toyonaga, Takuya and Naganawa, Mika and Gallezot, Jean-Dominique and Yang, Yanghong and Ibrahim, Waleed and Pittman, Brian and Cayir, Salih and Radhakrishnan, Rajiv and Angarita, Gustavo A and Holmes, Sophie E and Comley, Robert and Carson, Richard E and Finnema, Sjoerd J and Matuskey, David},
  title = {Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual‐Tracer Positron Emission Tomography Imaging Study},
  journal = {Movement Disorders},
  year = {2025},
  volume = {40},
  number = {12},
  pages = {2678--2687},
  doi = {10.1002/mds.70041}
}
Kostenlos starten →